Higgins V, Piercy J, Roughley A, Milligan G, Leith A, Siddall J, et al. From an individualized treatment plan that recognizes who you are, to specialized therapies based on the genetic profile of your specific cancer everything we do is centered around your unique needs. Immunotherapy was prescribed as 1L NSCLC treatment during COVID-19 for 64.2% (n=786) of patients and pre-COVID-19, for 47.8% (n=549). Most NSCLC tumours in Europe lack oncogenic driver mutations, rendering patients without targetable mutations ineligible to receive targeted therapies [7]. Figure 1. You may request a, Dana-Farber's Momentum of Discovery Campaign, Support Services for Patients and Families. 2020;5:2381468320922208. Together, these findings suggest that the increase in use of 1L immunotherapy in our study would have occurred regardless of the COVID-19 pandemic, due to evolving treatment landscape. Within the main sample, patients were recruited prospectively at the time of consultation, and the oversample was collected retrospectively. Physicians completed record forms (RFs) for the next six consecutive consulting patients with advanced NSCLC, who then voluntarily completed questionnaires. Lemos AEG, Silva GR, Gimba ERP, Matos ADR. Available at: https://www.who.int/health-topics/cancer#tab=tab_1. 2007;5:70. International Society for Pharmacoeconomics and Outcomes Research (ISPOR). Patient mean (SD) FACT-L score was 80.0 (18.8). Self-Reported Population Health: An International Perspective based on EQ-5D [Internet]. The greatest impact appeared to be in the UK, where management was affected for approximately 80% of patients, specifically fewer consultations and tests/investigations, a move to video and telephone consultations from the usual face-to-face appointments, and prescribed treatment changes. Brahmer JR, Rodrguez-Abreu D, Robinson AG, Hui R, Csszi T, Flp A, et al. IRVINE, Calif. July 27, 2022 City of Hope, one of the largest cancer research and treatment organizations in the United States, opens its visionary comprehensive cancer center in Orange County, California, creating a national model for delivering breakthrough research and pioneering treatments. Available from: https://www.healthit.gov/sites/default/files/hitech_act_excerpt_from_arra_with_index.pdf. The majority of biomarker results of patients were received before initiation of 1L treatment and therefore it may be assumed that these results were available to inform the 1L treatment prescription. There were an estimated 18 million cancer cases globally in 2020. Presented at Virtual ESMO-Immuno-Oncology Congress 2021, 811 December 2021. Why I traveled across the world for prostate cancer treatment Article This analysis of the characteristics and the current diagnostic landscape in patients with EGFR-WT/ALK-WT mNSCLC across Europe found that IO as well as chemotherapy-based regimens were frequently prescribed as 1L treatment. Only EGFR-wild-type/ALK-wild-type patients were included for analysis. Accessed 21 Feb 2023. OBJECTIVES: This study described healthcare resource utilization (HRU), costs, and treatment patterns among advanced or metastatic non-small cell lung cancer (a/mNSCLC) patients with different EGFR mutation types. Permission for use of the FACT questionnaire is obtained by contacting Dr. Cella at information@facit.org. Your gift to Dana-Farber supports our lifesaving mission. Patients with lung cancer are particularly vulnerable to COVID-19 infection, likely because abnormalities in their respiratory epithelium enable rapid entry of the virus into the lungs [42]. There were differences in the 1L treatment received (p<0.0001) by patients according to the histology of their NSCLC (squamous cell carcinoma, adenocarcinoma, large cell carcinoma and other) (Table 5); chemotherapy only was most commonly received by patients with adenocarcinoma, squamous cell carcinoma and large cell carcinoma. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data. We tailor each patient's treatment using an array of advanced approaches, including emerging treatments such as tumor-treating fields and MRI-guided laser ablation. The concentration of PD-L1 in cancer cells can be higher than 90%, making it a highly targetable protein. Hypertension and chronic pulmonary disease were the most frequently cited comorbid conditions experienced by patients with mNSCLC. J Immunother Cancer. There are many types of cancer treatment. Our teams of specialists work closely together to offer patients the latest therapies and clinical services, including access to innovative clinical trials. KEYNOTE-024 indicated improved QOL in patients prescribed pembrolizumab compared with platinum-doublet chemotherapy [40]. Non-small cell lung cancer (NSCLC) accounts for about 85% of all lung cancer cases [3, 4], with initial diagnosis most commonly in the advanced stages . The DSP methodology has been previously published and validated [17,18,19,20], with studies across many different disease areas implemented globally. Analyses were performed separately on the main sample and the retrospective oversample. All requests for access should be addressed directly to Hollie Bailey at hollie.bailey@adelphigroup.com. Originally published: Ann Oncol. BMC Cancer 2019;20:270. Breast cancer, lung cancer and colon cancer are among the most common cancers. Patient selection and sample sizes. Patient-reported outcomes from patients receiving immunotherapy or chemoimmunotherapy for metastatic non-small-cell lung cancer in clinical practice. Provided by the Springer Nature SharedIt content-sharing initiative. Diabetes Metab Syndr Obes. Article Around 50 per cent will be afraid to . The impact on management affected 78.7% (n=365) of patients in the UK, 32.4% (n=159) in Spain, 22.8% (n=109) in France, 20.9% (n=96) in Italy, and 19.6% (n=94) in Germany. Indeed, one country - Egypt, which had one of the highest rates of hepatitis C in the world - has already eradicated the disease, which can also lead to liver cancer, liver failure and death. Kidney cancer is a rising ailment the world over. Doctors at Memorial Sloan Kettering Cancer Center (MSK) pioneered advances in many types of cancer treatment for patients in 2022. Minimal Clinically Important Difference in EQ-5D: We Can Calculate it But Does That Mean We Should? At data collection, 1787 (75.3%) of patients were considered to be negative for COVID-19. BMJ Open. 1. In this stage, PSA and Grade Group levels . For this analysis, 1073 patients with EGFR-WT/ALK-WT mNSCLC were included (France: n=264 [24.6%], Germany: n=152 [14.2%], Italy: n=201 [18.7%], Spain: n=226 [21.1%], UK n=230 [21.4%]). Japan is equipped with the most advanced technologies needed to provide precise results. Here, real-world outcomes of first-line mono-IT and chemo-IT of advanced NSCLC treated within routine clinical practice at a single academic center in the Central Eastern European (CEE) region are . Front Oncol. The majority of patients had undergone a biopsy (n=2090; 88.1%), blood tests (n=2058; 86.7%), a CT chest scan (n=1955; 82.4%), and bronchoscopy (n=1541; 64.9%) during mNSCLC diagnosis in both diagnosis periods. The most common in 2020 (in terms of new cases of cancer) were: breast (2.26 million cases); lung (2.21 million cases); colon and rectum (1.93 million cases); prostate (1.41 million cases); skin (non-melanoma) (1.20 million cases); and Anderson P, Benford M, Harris N, Karavali M, Piercy J. The EQ-5D visual analogue score (VAS) ranges from 0 to 100, where higher scores indicate better quality of life (QoL) and the EQ-5D-5L index total score (French value set) and domain scores range from 0.00 to 1.00, where higher scores indicate better QoL [21, 22] Data for EQ-5D-5L and EQ-5D VAS were compared with normative reference values (EQ-5D, France-specific time to trade off value set 0.892; VAS, overall mean of the total for the five European countries, 77.8) [25]. The Catholic University Of Korea - Seoul St. Mary's Hospital. 2021;71:20949. Global comparison of cancer outcomes: standardization and correlation PubMed The median time to 1L treatment discontinuation in the 1L PD-L1-tested EGFR-WT/ALK-WT mNSCLC population who had progressed beyond 1L treatment was 4.0months (3.9, 4.0, and 4.5months for patients with PD-L1 expression of<1%, 149%, and50%, respectively). Health Policy. The DSP is a wholly owned Adelphi Real World product. In the 1L treatment setting, the majority of patients with PD-L1 expression of<1% (62.4% of 234 patients) and 149% (52.9% of 420 patients) received chemotherapy only; the majority of patients with PD-L150% received IO (80.9% of 367 patients). Death rates from cancer were falling before the pandemic. Chapter 3. Lung Cancer Treatment At MD Anderson, some of the nation's top lung specialists focus their extraordinary expertise on you. METHODS: This retrospective cohort study identified patients with EGFR mutation test results in linked NeoGenomics and IQVIA PharMetrics Plus databases between 01Jan2016 . The full course of 1L treatment was completed as intended by 75.9% of patients, and a complete response was achieved by 6.7% and a partial response by 69.2% of patients. The impact of SARS-CoV-2 (COVID-19) on 1L diagnostic and treatment patterns in patients with mNSCLC without EGFR and ALK mutations was also explored. Non-small cell lung cancer (NSCLC) is the most common type of primary lung cancer. Programmed Death Ligand-1 Immunohistochemistry: Friend or Foe? Patient characteristics for the EGFR-WT/ALK-WT mNSCLC population split by the period in which patients were diagnosed (pre-COVID-19 and during COVID-19) are shown in Table 8. Company size. The Netherlands. Patients of every age need care tailored to their needs. Arch Pathol Lab Med. Cancer care critically affected by USA drug shortages Cancer killed nearly 10 million people in 2020 and is a leading cause of death globally, according to the World Health Organization. Shortages in carboplatin and cisplatin are among the most critical to be affecting patient careboth of which are frontline chemotherapy drugs that are used to treat several . Proton therapy is a trusted form of radiation therapy capable of precisely targeting tumors while significantly sparing healthy tissue and decreasing the risk of side effects. No response was reported for twice as many patients with PD-L1 expression of<1% (31.7%) versus 149% (16.0%) and50% (16.7%). . Comprehensive, Compassionate Cancer Care in Dallas. For their most recent consultation, the majority of patients (87.7%) were seen face-to-face with their physician, ranging from 92.7% of patients in Spain, 96% in Germany, 96.3% in Italy, and 97.3% of patients in France. Explore one of the largest cancer clinical trials programs in the country. To KKW, Fong W, Cho WCS. As the oversample was retrospective, these patients did not complete these questionnaires. Lung. Bristol Myers Squibb did not influence the original survey through either contribution to the design of questionnaires or data collection. Nat Rev Clin Oncol. The likelihood of clinical benefit from anti-PD-1/PD-L1 agents in the 1L and 2L setting is related to the extent of PD-L1 expression on tumour cells [34]. 2015;10:124360. Our data look at specific time periods before and during the COVID-19 pandemic, and the findings are likely to change over time with the waves of infection within countries and as health systems adapted to operating with the disease. Passaro A, Bestvina C, Velez M, Garassino MC, Garon E, Peters S. Severity of COVID-19 in patients with lung cancer: evidence and challenges. As an oversample, physicians provided a further ten RFs specifically for patients with EGFR-wild-type mNSCLC: five patients diagnosed before March 2020 (pre-SARS-CoV-2 [COVID-19]) and five patients diagnosed from March 2020 (during COVID-19). Get involved! The Johns Hopkins Comprehensive Brain Tumor Center is one of the largest brain tumor treatment and research centers in the world. The MCID was>2 points for FACT-Lung Cancer Subscale score between patients in France and patients in Germany, Spain and the UK, but not between patients in Germany, Italy, Spain and the UK. Patient-reported EQ-5D VAS, EQ-5D utility index, and FACT are reported in Table 7. Over time, these in situ (stage . Bristol Myers Squibb is one of multiple subscribers to the DSP. Best cancer hospitals in the world Learn more about the brain tumor center. Indirect comparison with clinical trial data showed that global QoL scores were worse than those 1L single-agent IO, alongside higher than expected symptom burden [39]. Health-related quality-of-life results for pembrolizumab versus chemotherapy in advanced, PD-L1-positive NSCLC (KEYNOTE-024): a multicentre, international, randomised, open-label phase 3 trial. A complete response was achieved by 6.7% and a partial response by 69.2% of patients. 1993;11:5709. Using a checkbox, patients provided informed consent to take part in the survey. This delay can yield unexpected results when it comes to characterisation of real-world treatment use in clinical practice, particularly in this case the use of immunotherapy. This analysis of real-word patient data evaluated the characteristics and the current diagnostic landscape of patients with EGFR/ALK mNSCLC across five European countries, and the impact of COVID-19 on the treatment and management of this population. Stomach cancer - Diagnosis and treatment - Mayo Clinic J Immunol. The Functional Assessment of Cancer Therapy scale: development and validation of the general measure. All analyses were performed using the software package IBM SPSS Data Collection Survey Reporter Version 7.5 and STATA Version 16 (StataCorp LP, College Station, USA). The 2015 world health organization classification of lung tumors: impact of genetic, clinical and radiologic advances since the 2004 classification. Google Scholar. Symptom burden and quality of life in advanced non-small cell lung cancer patients in France and Germany. Patient mean (SD) FACT-G score was 62.8 (15.5), which was noticeably lower than the reported mean US population normative reference value of 80.1 [32]. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. Mean (SD) VAS scores ranged from 60.7 (19.86) for France to 71.2 (16.94) for Spain. Nevertheless, COVID-19 had a substantial impact on patients management across European countries, with at least one area of management impacted for over one-third of all patients. MD Anderson has been ranked by the United States as the No. Management of Lung Nodules and Lung Cancer Screening During the COVID-19 Pandemic: CHEST Expert Panel Report. 7 new breakthroughs in the fight against cancer - The World Economic Forum 2L+), the mean (SD) time to 1L treatment discontinuation of 5.1 (4.3) months. 2003;170(3):125766. Brown JA, Dorfman DM, Ma FR, Sullivan EL, Munoz O, Wood CR, Greenfield EA, Freeman GJ. The patient-reported questionnaire collected data on patient demographics, disease burden, and quality of life (QoL). Initially, the cancerous growth is confined to the duct or lobule ("in situ") where it generally causes no symptoms and has minimal potential for spread (metastasis). Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. The EQ-5D-5L utility index assessed health status with regard to mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. Aspartame sweetener to be declared possible cancer risk by WHO, say Some small stage 0 cancers can be treated by endoscopic resection. Each survey was performed in full accordance with relevant legislation at the time of data collection, including the US Health Insurance Portability and Accountability Act 1996 [27], and Health Information Technology for Economic and Clinical Health Act legislation [28]. The majority of patients had a current Eastern Cooperative Oncology Group performance status (ECOG PS) score of 1 (59.6%). Front Immunol. To stratify patients by treatment, 1L treatments were grouped by class. As such, immunotherapy has mainly been continued, but with the use of longer cycle options where available, and chemotherapy-based regimens have been used only when necessary [43]. Stage 1 treatment options. Mayo Clin Proc. Bristol Myers Squibb Receives European Commission Approval for Opdivo (nivolumab) plus Yervoy (ipilimumab) with Two Cycles of Chemotherapy for First-Line Treatment of Metastatic Non-Small Cell Lung Cancer. PubMed If you have cancer, palliative care can help relieve pain and other symptoms. J Clin Oncol. What are the most advanced treatment modalities in cancer treatment Jayadevappa R, Cook R, Chhatre S. Minimal important difference to infer changes in health-related quality of life-a systematic review. Palliative care. Bailey H, Lee A, Eccles L, Yuan Y, Khela K, Hall J, Last M, Varol N. The Evolving Diagnostic And Treatment Landscape In Metastatic Non-Small Cell Lung Cancer (mNSCLC) Across Europe A Real World Evidence Survey. Of 2372 patients with EGFR-WT/ALK-WT mNSCLC, pembrolizumab (53.5%) and carboplatin (45.4%) were the most frequent 1L therapies (either as monotherapy or in combination) used both pre-COVID-19 (n=1147) and during COVID-19 (n=1225). Dana-Farber assumes no liability for inaccuracies that may result from using this third-party tool, which is for website translation and not clinical interactions. All authors were involved in the conception or design, or analysis and interpretation of data; drafting and revising the article; providing intellectual content of critical importance to the work described; and final approval of the version to be published, and therefore meet the criteria for authorship in accordance with the International Committee of Medical Journal Editors guidelines. In this analysis of the impact of the COVID-19 pandemic, there were minimal differences in the demographics and clinical characteristics of patients with EGFR-WT/ALK-WT mNSCLC diagnosed in the pre-COVID-19 period and diagnosed during the COVID-19 period.Potential delays in diagnosis during the pandemic may be suggested by the greater difference between the frequency of a stage IVb and stage IVa diagnosis within the group diagnosed during COVID-19 than that found within the pre-COVID-19 group, although there was no apparent change in the tests and assessments used within the two diagnostic periods. Kerr KM, Hirsch FR. Summary of the HIPAA Privacy Rule; 2003. 2014;2(9):84656. Fact sheet 15. The DSP uses survey techniques to collect anonymized data that is analyzed in aggregated form. Physician and patient data were pseudo-anonymized. 1). Lung Cancer. ALK, anaplastic lymphoma kinase; aNSCLC, advanced non-small cell lung cancer; COVID-19, SARS-CoV-2; EGFR, epidermal growth factor receptor; EGFR-WT/ALK-WT, (i.e., no sensitising EGFR mutation or ALK translocation; wild type); mNSCLC, metastatic non-small cell lung cancer. Physicians meeting the inclusion criteria and willing to participate first completed an attitudinal survey regarding the management and treatment of patients with mNSCLC. Real-world outcomes of PD-L1 inhibitors combined with thoracic Using a checkbox, patients provided informed consent to take part in the survey. PubMed Central It's estimated that one in two people will be diagnosed with cancer in their lifetime. Accessed on 21 Feb 2023. 2000;192(7):102734. The World Health Organization's cancer research arm, the International Agency for Research on Cancer (IARC), has conducted a safety review of aspartame and will publish a report next month. A real-world outcomes study of patients with mNSCLC who received IO or IO+chemotherapy showed that patient QoL (European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire Core 30 [QLQ-30]) was similar between those on IO and IO+chemotherapy and not related to weeks on these treatments. Google Scholar. 2020;136:1329. Because of the lack of modern equipment in many countries, cancer is often detected at advanced stages, when treatment is less effective. Your US state privacy rights, We can help you find a doctor. 2020. https://news.bms.com/news/details/2020/Bristol-Myers-Squibb-Receives-European-Commission-Approval-for-Opdivo-nivolumab-plus-Yervoy-ipilimumab-with-Two-Cycles-of-Chemotherapy-for-First-Line-Treatment-of-Metastatic-Non-Small-Cell-Lung-Cancer/default.aspx. Patient characteristics for the total mNSCLC sample who were EGFR-WT/ALK-WT (n=1073) are shown in (Table 1). For the oversample, physicians provided information retrospectively on 10 patients with EGFR-WT mNSCLC: five patients diagnosed during the pre-COVID-19 period (defined as 1 September 2019 to 29 February 2020; prior to when all five European countries went into lockdown due to the COVID-19 pandemic) and five patients diagnosed during the COVID-19 pandemic (1 March 2020 to the time of data collection). Among the total EGFR-WT/ALK-WT mNSCLC population (n=1073), advanced treatment was mostly chemotherapy only (39.2%) followed by immune-oncology monotherapy (IO; 35.0%) (Table 3). Presented at Virtual ESMO-Immuno-Oncology Congress 2021, 811 December 2021. Dana-Farber Cancer Institute remains true to Dr. Sidney Farber's vision of a cancer center that is as dedicated to discoveries in cancer research as it is to delivering compassionate, patient-centered care. https://seer.cancer.gov/statfacts/html/lungb.html Accessed 21 Feb 2023. In France, Germany, Italy, and Spain, telephone and video/online consultations were held with<5% and2% of patients, respectively. Decision making in the treatment of patients with lung cancer during the COVID-19 pandemic has also presented challenges as to whether to offer, modify, postpone or cancel treatments [46]. World's Best Specialized Hospitals 2021 - Newsweek PubMed Accessed 21 Feb 2023. PD-1 expression on lymphocytes and its interaction with its ligands on tumour and immune cells are the basis of anti-tumour immunity and PD-1 inhibition in cancer immunotherapy [16]. Small cell lung cancer (SCLC) accounts for approximately 15% of all newly diagnosed lung cancers and is highly aggressive, with approximately two-thirds of patients having advanced disease progression, known as extensive stage SCLC (ES-SCLC), at the time of diagnosis [].In the pre-immunotherapy era, thoracic radiotherapy (TRT) plays an important role in the treatment of ES-SCLC. Treatment patterns and outcomes of patients with metastatic non-small cell lung cancer in five European countries: a real-world evidence survey, https://doi.org/10.1186/s12885-023-11074-z, https://gco.iarc.fr/today/data/factsheets/cancers/15-Lung-fact-sheet.pdf, https://www.cancer.net/cancer-types/lung-cancer-non-small-cell/statistics, https://seer.cancer.gov/statfacts/html/lungb.html, https://www.esmo.org/guidelines/guidelines-by-topic/lung-and-chest-tumours/clinical-practice-living-guidelines-metastatic-non-small-cell-lung-cancer, https://euroqol.org/publications/user-guides/, https://www.ncbi.nlm.nih.gov/books/NBK500364/, http://www.hhs.gov/sites/default/files/privacysummary.pdf, https://www.healthit.gov/sites/default/files/hitech_act_excerpt_from_arra_with_index.pdf, https://www.ispor.org/docs/default-source/presentations/1066.pdfI, https://qol.thoracic.org/sections/instruments/fj/pages/fact-f.html, https://doi.org/10.1016/S1470-2045(17)30690-3, https://www.who.int/health-topics/cancer#tab=tab_1, https://news.bms.com/news/details/2020/Bristol-Myers-Squibb-Receives-European-Commission-Approval-for-Opdivo-nivolumab-plus-Yervoy-ipilimumab-with-Two-Cycles-of-Chemotherapy-for-First-Line-Treatment-of-Metastatic-Non-Small-Cell-Lung-Cancer/default.aspx, https://www.esmo.org/guidelines/cancer-patient-management-during-the-covid-19-pandemic/lung-cancer-in-the-covid-19-era, http://creativecommons.org/licenses/by/4.0/, http://creativecommons.org/publicdomain/zero/1.0/. Next big advance in cancer treatment may be a vaccine - The Mercury News The MCID for FACT-L for advanced NSCLC is 23-point difference on the lung cancer subscale [33]. European Society for Medical Oncology. Best Hospitals for Cancer in Dallas-Fort Worth, TX The discovery of targetable mutations in genes other than EGFR and ALK, such as c-ros oncogene 1 (ROS1) and v-Raf murine sarcoma viral oncogene homolog B (BRAF) has led to the development of additional targeted therapies in NSCLC, specific to each genomic mutation [11]. A Lee, L Eccles, Y Yuan, and N Varol are employees of Bristol Myers Squibb, and H Bailey, M Last, H Burlison, and C Forshaw are employees of Adelphi Real World. Fort Lauderdale, Florida. As patients consult at random, the patient sampling method is considered to generate a patient sample representative of the typical mNSCLC consulting population. Each survey was performed in full accordance with relevant legislation at the time of data collection, including the US Health Insurance Portability and Accountability Act 1996, and Health Information Technology for Economic and Clinical Health Act legislation. Best Hospitals for Prostate Cancer Surgery - US News Health The majority of patients (n=1010/1073, 95%) were tested for PD-L1 status at advanced diagnosis (Table 2). "Advanced cancer" is an ambiguous term. The majority of these patients (55.6%) had adenocarcinoma. Copyright 2023 Dana-Farber Cancer Institute Article Still, doctors predict that the absence of the powerful chemotherapies may hurt patients most. Toshiba Heavy-Ion Therapy System Awarded by Yonsei University Health Functional Assessment of Cancer Therapy: Fatigue (FACT-F). 1L immunotherapy, either as monotherapy or combination therapy, was prescribed in 64.2% of the population diagnosed during COVID-19 and 47.8% of patients diagnosed pre-COVID-19; the between-group difference was mostly observed in immunotherapy combination therapy (Table 11).